China’s Intravenous Solution Producers Expect Fair Fight With Foreign Competitors
This article was originally published in PharmAsia News
Executive Summary
Baxter recently announced an additional $146 million investment to expand its intravenous solution capacity in China (PharmAsia News, May 18, 2009). The move marks foreign corporations' strategy to tighten their monopoly on the top-grade hospital market, further putting the squeeze on domestic firms. Currently, most of China's 400-plus intravenous solution providers comprise workshops with low-end products such as nutrient fluids. While MNCs enjoy high profits, locals fight based on price cutting. Industry analysts believe that the healthcare reform brings huge opportunity to mid- and low-end producers, spelling a fresh round of competition that will lead to a shake-up. However, others point out that domestic firms cannot contend against international players if healthcare policies remain preferential for the latter. (Click here for more - Chinese Language)
You may also be interested in...
Baxter Plans $146.5 Million Investment In China Dialysis-Related Plants
Baxter International plans to invest $146.5 million in China to increase production capacity for dialysis products at four of its plants. The U.S.-based company plans to expand its products relying on intravenous and peritoneal solutions to meet Baxter China General Manager Paul Vibert's goal of double-digit sales growth this year. Baxter has plants in Guangzhou, Suzhou, Tianjin and Shanghai. (Click here for more
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.